GHRP-2 5 MG

GHRP-2 5 mg – Peptide Hubs

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide used in experimental models to trigger growth hormone release via ghrelin receptor activation. The 5 mg vial by Peptide Hubs offers researchers a potent, lab-grade tool to study GH elevation, recovery, metabolism, and hormonal feedback loops. It is particularly valued in studies involving aging, tissue repair, and GH deficiency.

How GHRP-2 Works

GHRP-2 binds to the GHS-R1a receptor in the pituitary and hypothalamus, leading to a sharp increase in pulsatile GH release. This action mimics the effect of endogenous ghrelin, though with greater specificity and potency. Unlike GHRP-6, GHRP-2 has a lower appetite-stimulating effect, making it suitable for studies focused on lean mass maintenance, IGF-1 upregulation, and metabolic enhancement.

For a deeper overview of its GH-releasing effects and receptor interactions, visit this NIH review on GHRPs and ghrelin receptor agonists.

Key Research Applications

GHRP-2 5 mg is used across various research areas, including:

• Growth hormone stimulation in GH-deficient models
• Body composition optimization and muscle retention
• Fat metabolism and recovery studies
• Sleep regulation and circadian rhythm improvement

GHRP-2 is often co-administered with CJC-1295 DAC for synergistic GH pulse enhancement. Researchers also combine it with GHK Basic for collagen and wound healing protocols.

Suggested Experimental Use

• Dosage Range: 100–300 mcg per dose, 1–3x daily
• Administration: Subcutaneous injection (typically fasted)
• Duration: 4–12 week cycles depending on experimental goals

Stacking Possibilities

GHRP-2 is commonly included in research stacks with other Peptide Hubs products:

• DSIP – to explore hormonal feedback during sleep recovery cycles
• Cartalax – for soft tissue regeneration during anabolic support research
• Chonluten – to stabilize immune response during metabolic enhancement models
• B7-33 – for anti-fibrotic modulation during cell proliferation studies

Safety and Legal Status

GHRP-2 is not FDA-approved and is intended exclusively for research purposes. It does not aromatize or affect liver enzymes and is not known to be hepatotoxic or carcinogenic. Transient prolactin or cortisol elevation has been observed in some models at high doses. For verified studies and regulatory updates, consult ClinicalTrials.gov.

Frequently Asked Questions